Smart dosing of rituximab may prevent relapse in rare vasculitis
NCT ID NCT01731561
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times
Summary
This study tested whether giving rituximab based on blood markers (ANCA and CD19) works as well as giving it on a fixed schedule to prevent relapses in people with ANCA-associated vasculitis. 166 adults in remission were randomly assigned to one of two rituximab plans and followed for 28 months. The goal was to see which approach better prevents disease flares while keeping side effects low.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cochin Hospital
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.